Innovative Pipeline InMed Pharmaceuticals specializes in developing proprietary small molecule drug candidates targeting CB1/CB2 receptors, with ongoing programs for Alzheimer's, ocular, and dermatological conditions, presenting opportunities to collaborate or supply complementary research and development services.

Strong Industry Focus As a biotechnology research firm with a focus on cannabinoids and neurodegenerative diseases, InMed is positioned to partner with organizations seeking innovative solutions in pain management, neuroprotection, and dermatology sectors.

Recent Leadership Expansion The appointment of new board members and scientific advisors indicates strategic growth and potential openness to collaborations, which can be leveraged to engage with decision-makers in partnership or funding discussions.

Funding & Growth With recent plans to secure nearly CAD 10 million in funding, InMed is actively expanding its research capabilities, creating opportunities for investment, joint ventures, or supply chain solutions as they accelerate product development.

Market Engagement Participation in industry conferences such as the Alzheimer's Association International Conference demonstrates active market engagement, providing avenues to connect with key stakeholders, collaborators, and clients interested in cannabinoid-based therapeutics.